28-color single tube for flow cytometric assessment of myeloid maturation, myeloid neoplasia, and acute myeloid leukemia minimal/measurable residual disease

被引:0
作者
Gao, Qi [1 ]
Chan, Alexander [1 ]
Zhang, Jingping [1 ]
Sun, Xiaotian [1 ]
Burke, Amanda [1 ]
Miu, Olivia [1 ]
Nguyen, Nghia [1 ]
Zhang, Shu Jie [1 ]
Reminick, Jennifer [1 ]
Wardrope, Jessica [1 ]
Roshal, Mikhail [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, New York, NY USA
关键词
AML; assay validation; LLoD; LLoQ; MPP; MRD; stem cells; IMMUNOPHENOTYPIC ANALYSIS; CELL; AML; EXPRESSION; DIAGNOSIS; FREQUENCY; SUBTYPES; REVEALS; ORIGIN; MARKER;
D O I
10.1002/cyto.b.22233
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Flow cytometry (FC) is an indispensable tool for myeloid neoplasia (MN) diagnosis, and the cell of origin has clinical diagnostic and prognostic significance. However, the complex maturational pathways within the blast compartment complicate the detection of the abnormal population at the minimal/measurable disease (MRD) level using the difference from normal approach. The analysis could be simplified by separating the blast compartment into maturation-defined stages with relatively uniform phenotypes as reference populations. This requires a relatively extensive panel of antibodies to define maturation stages and simultaneously detect the common deviations from the normal pattern. We validated a single tube 28-color clinical assay for MN assessment and acute myeloid leukemia (AML) MRD detection assisted by the precise maturation stage assignment. The new assay uses a previously described 21-antigen backbone, with the additions of CD10, CD36, CD42b, CD45RA, CD90, CD105, and CD371. Validation was performed using 37 normal samples and 151 MN follow-up samples in a split-sample fashion comparing the new assay to the legacy 3-tube, 21-antigen assay. Dilution studies were performed to establish assay sensitivity. A new analysis framework relying on comparison to well-defined maturational stages was established for MRD analysis. The assays showed 100% qualitative concordance with excellent quantitative concordance. Dilution studies yielded a limit of detection of 0.01%. The addition of new antibodies allowed for consistent comparisons of candidate abnormal populations to well-defined normal maturation stages through traditional FC plots and Uniform Matrix Approximation and Projection assessments. This new single-tube, 28-color clinical assay allows for efficient MN assessment in clinical settings. It reliably detects MRD levels of abnormal myeloid cells because the expanded panel allows for precise comparison to defined lineage commitment maturational stages. Lastly, it provides high information density while reducing equipment use, reagent use, and technical labor.
引用
收藏
页数:14
相关论文
共 47 条
  • [31] The proportion of CD34+ CD38low or neg myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia
    Roshal, M.
    Chien, S.
    Othus, M.
    Wood, B. L.
    Fang, M.
    Appelbaum, F. R.
    Estey, E. H.
    Papayannopoulou, T.
    Becker, P. S.
    [J]. LEUKEMIA, 2013, 27 (03) : 728 - 731
  • [32] Roshal Mikhail, 2025, Am J Clin Pathol, DOI 10.1093/ajcp/aqae187
  • [33] Development of a 27-color panel for the detection of measurable residual disease in patients diagnosed with acute myeloid leukemia
    Soh, Kah Teong
    Conway, Alexis
    Liu, Xiaojun
    Wallace, Paul K.
    [J]. CYTOMETRY PART A, 2022, 101 (11) : 970 - 983
  • [34] High-sensitivity flow cytometric assays: Considerations for design control and analytical validation for identification of Rare events
    Sommer, Ulrike
    Eck, Steven
    Marszalek, Laura
    Stewart, Jennifer J.
    Bradford, Jolene
    McCloskey, Thomas W.
    Green, Cherie
    Vitaliti, Alessandra
    Oldaker, Teri
    Litwin, Virginia
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2021, 100 (01) : 42 - 51
  • [35] MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome
    Stavropoulou, Vaia
    Kaspar, Susanne
    Brault, Laurent
    Sanders, Mathijs A.
    Juge, Sabine
    Morettini, Stefano
    Tzankov, Alexandar
    Iacovino, Michelina
    Lau, I-Jun
    Milne, Thomas A.
    Royo, Helene
    Kyba, Michael
    Valk, Peter J. M.
    Peters, Antoine H. F. M.
    Schwaller, Juerg
    [J]. CANCER CELL, 2016, 30 (01) : 43 - 58
  • [36] Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance
    Sui, Jing-Ni
    Chen, Qiu-Sheng
    Zhang, Yun-Xiang
    Sheng, Yan
    Wu, Jing
    Li, Jun-Min
    Weng, Xiang-Qin
    Chen, Bing
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (05) : 528 - 538
  • [37] Swerdlow SH., 2017, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, VRevised 4th edition
  • [38] High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
    Terwijn, Monique
    van Putten, Wim L. J.
    Kelder, Angele
    van der Velden, Vincent H. J.
    Brooimans, Rik A.
    Pabst, Thomas
    Maertens, Johan
    Boeckx, Nancy
    de Greef, Georgine E.
    Valk, Peter J. M.
    Preijers, Frank W. M. B.
    Huijgens, Peter C.
    Draeger, Angelika M.
    Schanz, Urs
    Jongen-Lavrecic, Mojca
    Biemond, Bart J.
    Passweg, Jakob R.
    van Gelder, Michel
    Wijermans, Pierre
    Graux, Carlos
    Bargetzi, Mario
    Legdeur, Marie-Cecile
    Kuball, Jurgen
    de Weerdt, Okke
    Chalandon, Yves
    Hess, Urs
    Verdonck, Leo F.
    Gratama, Jan W.
    Oussoren, Yvonne J. M.
    Scholten, Willemijn J.
    Slomp, Jennita
    Snel, Alexander N.
    Vekemans, Marie-Christiane
    Loewenberg, Bob
    Ossenkoppele, Gert J.
    Schuurhuis, Gerrit J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) : 3889 - +
  • [39] Aberrant marker expression patterns on the CD34+CD38-stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission
    van Rhenen, A.
    Moshaver, B.
    Kelder, A.
    Feller, N.
    Nieuwint, A. W. M.
    Zweegman, S.
    Ossenkoppele, G. J.
    Schuurhuis, G. J.
    [J]. LEUKEMIA, 2007, 21 (08) : 1700 - 1707
  • [40] Human haematopoietic stem cell lineage commitment is a continuous process
    Velten, Lars
    Haas, Simon F.
    Raffel, Simon
    Blaszkiewicz, Sandra
    Islam, Saiful
    Hennig, Bianca P.
    Hirche, Christoph
    Lutz, Christoph
    Buss, Eike C.
    Nowak, Daniel
    Boch, Tobias
    Hofmann, Wolf-Karsten
    Ho, Anthony D.
    Huber, Wolfgang
    Trumpp, Andreas
    Essers, Marieke A. G.
    Steinmetz, Lars M.
    [J]. NATURE CELL BIOLOGY, 2017, 19 (04) : 271 - +